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Newcastle disease virus (NDV) V protein is crucial for viral interferon (IFN) 52 
antagonism and virulence, determining its host range restriction. However, little 53 
information is available on the B cell epitopes of V protein and the subcellular 54 
movement of V protein in the process of NDV infection. In this study, the monoclonal 55 
antibody (mAb) clone 3D7 against genotype VII NDV V protein was generated by 56 
immunizing mice with a purified recombinant His-tagged carboxyl-terminal domain 57 
(CTD) region of V protein. Fine epitope mapping analysis and B-cell epitope 58 
prediction indicated that mAb 3D7 recognized a linear epitope 152RGPAELWK159, 59 
which is located in the V protein CTD region. Sequence alignment showed that the 60 
mAb clone 3D7-recognized epitope is highly conserved among Class II genotype VII 61 
NDV strains, but not among other genotypes, suggesting it could serve as a genetic 62 
marker to differentiate NDV genotypes. Furthermore, the movement of V protein 63 
during NDV replication in infected cells were determined by using this mAb. It was 64 
found that V protein localized around the nucleus during virus replication. The 65 
establishment of V protein-specific mAb and identification of its epitope extend our 66 
understanding of the antigenic characteristics of V protein and provide a basis for the 67 
development of epitope-based diagnostic assays. 68 
 69 
1. Introduction 70 
Newcastle disease (ND) is one of the most serious infectious diseases of birds 71 
causing major economic losses to the poultry industry (Aldous and Alexander, 2001; 72 
Dimitrov et al., 2016). Its causative agent, virulent Newcastle disease virus (NDV), 73 
belongs to the genus Avulavirus, in the subfamily Paramyxovirinae, family 74 
Paramyxoviridae, order Mononegaviriales (de Leeuw and Peeters, 1999). 75 
Phylogenetically, NDVs have been classified into two major categories, class I and 76 
class II (Czegledi et al., 2006; Gould et al., 2003). Class I NDVs are occasionally 77 
isolated from wild aquatic birds and domestic poultry and all but one are nonvirulent 78 
(Liu et al., 2009; Mia Kim et al., 2007). Class II NDVs, which were recently 79 
subcategorized into 18 genotypes, are genetically and phenotypically more diverse, 80 
and exhibit a wider range of virulence (Diel et al., 2012; Dimitrov et al., 2016; Miller 81 
et al., 2010; Ramey et al., 2013). 82 
 83 
NDV has a negative-sense, single-stranded continuous RNA genome of 15,186, 84 
15,192 or 15,198 nucleotides (nt) that contains six genes in the order 3’-NP-P-M-F-85 
HN-L-5’, encoding the six viral proteins nucleoprotein, phosphoprotein, matrix 86 
protein, fusion protein, hemagglutinin-neuraminidase and large protein (Yusoff and 87 
Tan, 2001). Two additional proteins, V and W, are encoded by mRNAs derived from 88 
the P gene via RNA editing (Qiu et al., 2016a; Steward et al., 1993). In the process 89 
of P gene transcription, some transcripts have inserts of one or more pseudo-90 
template G nucleotides behind the RNA-editing site, leading to open reading frame 91 
(ORF) frameshift. The reported proportions of protein-encoding mRNAs in NDV-92 
infected cells are about 68% for P, 29% for V, and 2% for W (Mebatsion et al., 2001; 93 
Qiu et al., 2016a). P, V and W protein shared a common N-terminal moiety of ORF 94 
and contained unique C-terminal moiety (Huang et al., 2003; Park et al., 2003a). 95 
 96 
The V protein of paramyxoviruses is characterized by a unique cysteine-rich 97 
carboxyl-terminal domain (CTD), which binds two zinc atoms (Paterson et al., 1995; 98 
Steward et al., 1995) and is important for viral interferon (IFN) antagonism in a 99 
variety of ways (Horvath, 2004b). The V protein of parainfluenza virus 5 (PIV5) and 100 
mumps virus (MuV) target signal transducer and activator of transcription 1 (STAT1) 101 
for proteasome-mediated degradation through assembly of a degradation complex 102 
containing signal transducer and activator of transcription 2 (STAT2), damaged DNA 103 
binding protein 1, and cullin 4 A (Didcock et al., 1999; Kubota et al., 2001). The V 104 
proteins of Nipah virus and Hendra virus inhibit cellular responses to IFN through 105 
binding and cytoplasmic sequestration of both STAT1 and STAT2 (Rodriguez et al., 106 
2002, 2003). Measles virus (MV) V protein inhibits host IFN-induced transcriptional 107 
responses by preventing IFN-induced STAT1 and STAT2 nuclear import (Palosaari 108 
et al., 2003). 109 
 110 
Similar to PIV5, NDV V protein is a structural component of virions and considered 111 
an effector for IFN antagonism (Paterson et al., 1995; Steward et al., 1995); 112 
however, its underlying mechanism is unknown. Based on reverse genetics, several 113 
V-deficient NDV mutants have been recovered, which were much more sensitive to 114 
the antiviral effects of IFN (Alamares et al., 2010; Mebatsion et al., 2001; Park et al., 115 
2003a; Qiu et al., 2016b); resistance to IFN is restored when V protein is re-116 
expressed in infected cells (Park et al., 2003a). NDV inhibits IFN through the C-117 
terminal region of the V protein, which promotes degradation of phosphorylated 118 
STAT1 and blocks IFN signaling (Huang et al., 2003; Park et al., 2003b; Qiu et al., 119 
2016b). 120 
 121 
Due to lack of commercial antibodies against V protein, little is known about 122 
structural and antigenic differences of V protein between different NDV strains, nor 123 
the detailed IFN antagonism mechanism of NDV V protein. In this study, a 124 
recombinant protein containing the CTD domain of NDV V protein was used as an 125 
antigen for production of mouse hybridomas that secreted an anti-V protein 126 
monoclonal antibody (mAb). Sensitivity and specificity of the anti-V mAb was 127 
examined by enzyme-linked immunosorbent assay (ELISA), Western blot (WB) and 128 
indirect immunofluorescence assay (IFA). The epitope recognized by the mAb were 129 
also identified by WB and ELISA assay. Our study indicated that the mAb we 130 
developed could be a useful tool for investigating the antigenic structure and function 131 
of NDV V protein. 132 
 133 
2. Materials and methods 134 
2.1. Virus, cells and plasmids 135 
NDV strains used in this study, La Sota/46, Mukteswar, Queensland V4, Herts/33, 136 
F48E8 and Hitchner B1, were from China Institute of Veterinary Drug Control. 137 
Pi/China/SD/2012/132 (designated ND132 in this study), Pi/China/SD/2012/167 138 
(ND167), CN/ZJ-1/00 (ZJ-1), JSD0812 and JS-7-05-Ch (HM) were previously 139 
isolated on mainland China (Dai et al., 2014; Qiu et al., 2011). All viruses were 140 
maintained in our laboratory (Detailed information on NDV strains is in Table 1). All 141 
viruses were propagated in 9- to 11-day-old specific-pathogen-free chicken 142 
embryonated eggs as previously described (Gough et al., 1988). Fresh allantoic fluid 143 
was harvested from embryonated eggs dead between 24 and 120 h after inoculation 144 
and kept at -80 °C. DF-1, HeLa and SP2/0 cells were from the American Type 145 
Culture Collection and cultured in Dulbecco's modified Eagle's medium (DMEM; 146 
Gibco, Grand Island, NY) or RPMI 1640 medium (Gibco) containing 10% fetal bovine 147 
serum (FBS, Gibco) at 37 °C and 5% CO2. Prokaryotic expression plasmid pET-28a-148 
ZJ1/VCD encoding the C-terminal domain of ZJ1 and eukaryotic expression plasmid 149 
pFLAG-ZJ1-V encoding the complete V protein of ZJ1 were constructed previously 150 
(Qiu et al., 2016b). 151 
 152 
2.2. Expression and purification of recombinant protein 153 
The His-tagged CTD region of V protein (VCD) from strain ZJ1 was prepared, 154 
purified and quantified according to previous reports (Qiu et al., 2016b). The pET-155 
28a-ZJ1/VCD was transformed into Escherichia coli. (E. coli.) BL2l and induced at 156 
37 °C for 8 h with 1 mM isopropyl-β-D-thiogalactoside. Bacteria were harvested by 157 
centrifugation at 5000g and washed for three times in phosphate buffered saline 158 
(PBS). Pellets were resuspended in buffer A (50 mM Tris-HCl pH 8.0, 300 mM NaCl, 159 
20 mM imidazole, 1 mM phenylmethylsulfonyl fluoride) supplemented with lysozyme 160 
(0.4 mg/mL) and DNase I (10 μg/mL). After 30 min with gentle shaking, bacteria were 161 
sonicated on ice. After centrifugation at 13,000 g for 20 min at 4 °C, pellets were 162 
collected and solubilized overnight with gentle shaking at 4 °C in 50 mM Tris-HCl (pH 163 
8.0) containing 8 M urea, 0.5 M NaCl, 5 mM 2-mercaptoethanol and 5 mM imidazole. 164 
Supernatant containing solubilized inclusion bodies was collected after centrifugation 165 
at 12,000 g for 15 min. Purified recombinant protein was harvested from 166 
supernatants using Ni-NTA His•Bind Resin (Novagen, Madison, WI, USA) according 167 
to the manufacturer’s instruction. Recombinant His-tagged VCD (His-VCD) protein 168 
was confirmed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-169 
PAGE) and WB with anti-His (Sigma-Aldrich, St. Louis, MO). Protein concentration 170 
was determined using Bio-Rad protein assay reagent (Bio-Rad, Hercules, CA). 171 
 172 
2.3. Immunization of mice and establishment of hybridomas 173 
Six-week-old female BALB/c mice (SPF grade) were purchased from the Shanghai 174 
SLAC Laboratory Animal Co., Ltd. (China). The His-VCD protein was emulsified with 175 
an equal amount of Freund’s complete adjuvant (Sigma-Aldrich, USA) and 176 
subcutaneously immunized the mice in the abdomen with 50 μg His-VCD protein for 177 
each mouse. Four weeks after priming, mice were boosted four times in 2-week 178 
intervals by intraperitoneal injection of 100 μg His-VCD protein per mouse. Five days 179 
after last injection, spleen cells were collected from immunized mice, washed twice 180 
with RPMI 1640 medium, and mixed and fused with logarithmically growing SP2/0 181 
myeloma cells in a ratio of 5:1 in the presence of polyethylene glycol 4000 (Sigma–182 
Aldrich, St. Louis, MO, USA). Treated cells were suspended in HAT (RPMI 1640 183 
medium containing 20% FBS, 100 mg/mL streptomycin, 100 IU/mL penicillin, 184 
100 mM hypoxanthine, 16 mM thymidine, and 400 mM aminopterin), and plated into 185 
96-well tissue culture plates at 1 × 105 cells per well in 200 μL media. After 186 
cultivation at 37 °C at 5% CO2 for 10 days, medium was detected for anti-VCD 187 
antibodies by indirect ELISA with His-VCD protein. Positive hybridoma cells were 188 
subcloned though a limited dilution method several times until monoclonal hybridoma 189 
cells were established following standard procedures. Hybridoma cells were cultured 190 
in the abdominal cavity of liquid-paraffin-primed BALB/c mice to obtain ascitic fluid. 191 
Globulin fractions were precipitated with 2 M (NH4)2SO4 and purified by gel filtration 192 
with Sephacryl S-200 HR (GE Healthcare UK Ltd.). MAb clones were tested for 193 
immunoglobulin class/subclass using the SBA Clonotyping System 194 
(SouthernBiotech, USA). 195 
 196 
2.4. Indirect enzyme-linked immunosorbent assays 197 
Purified ZJ1-VCD protein or fresh allantoic fluid for distinct NDV strains treated with 198 
an equal amount of 0.1% SDS at 100 °C for 10 min were used as detection antigens. 199 
Microtiter ELISA plates with 96 wells were coated with 1:200 dilutions of prepared 200 
allantoic fluid or 1 ng/μL purified ZJ1-VCD protein in 100 μL carbonate buffer solution 201 
(CBS) per well. After cultivation at 4 °C overnight, ELISA plates were washed three 202 
times with PBS containing 0.05% Tween-20 (PBST) and blocked with 300 μL/well 203 
5% skim milk powder in PBST for 2 h at 37 °C. Hybridoma cultured medium or 204 
antibodies were plated into coated ELISA plates, 100 μL per well, and incubated at 205 
37 °C for 1 h. After washing three times with PBST, plates were incubated with 206 
1:6000 diluted horseradish peroxidase-conjugated goat anti-mouse IgG (Santa Cruz, 207 
CA, USA) for 1 h at 37 °C. To each well, 100 μL 3,3′,5,5′-tetramethylbenzidine 208 
(Sigma-Aldrich, USA) was added and absorbance was measured at 450 nm in a 209 
microplate reader (Synergy 2, BioTek). 210 
 211 
2.5. Specificity of mAbs for NDV genotypes 212 
DF-1 cells were cultured in 6-well plates, washed 3 times with PBS, and incubated 213 
with NDV strains at multiplicity of infection (MOI) 5 in 600 μL DMEM per well at 37 °C 214 
for 30 min. Supernatants were discarded and cells cultured in DMEM containing 2% 215 
FBS (Gibco). At indicated time points, cells were washed thoroughly and subjected 216 
to IFA and WB assays with anti-VCD mAbs. 217 
 218 
2.6. Western blots 219 
Cells harvested at indicated time points were washed three times with PBS and 220 
lysed with RIPA buffer (50 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% v/v NP-40, 1% 221 
w/v sodium deoxycholate, 0.1% w/v sodium dodecyl sulfate, 1 mM 222 
phenylmethanesulfonyl fluoride, 1 mM Na3VO4, 1 mM NaF, 0.15 μM aprotinin, 1 μM 223 
leupeptin, and 1 μM pepstatin). Lysates were incubated at 100 °C for 10 min after 224 
addition of 5× SDS-PAGE loading buffer (250 mM Tris-HCl, pH 6.8, 10% SDS, 0.5% 225 
bromophenol blue, 50% glycerol, 5% β-mercaptoethanol), and proteins separated by 226 
SDS-PAGE on 10% polyacrylamide gels before transferring to nitrocellulose 227 
membranes (Millipore, Billerica, MA, USA). Membranes were blocked overnight at 228 
4 °C in Tris-HCl buffer solution (TBS) containing 5% skim milk, then for 2 h with anti-229 
VCD mAb, anti-NP mAb(Zhan et al., 2014) or anti-FLAG (positive control). After 230 
incubation with 1:6000 diluted HRP-goat anti-mouse IgG (Santa Cruz) in TBS for 1 h 231 
at room temperature, blots were visualized using an enhanced chemiluminescence 232 
detection system (Thermo Fisher Scientific, Waltham, MA, USA). 233 
 234 
2.7. Indirect immunofluorescence assays 235 
MAbs were detected in IFA according to previously described procedures (Sun et al., 236 
2017). DF1 cells cultured on glass coverslips were infected with ZJ1 virus at a MOI 237 
of 5. Cells were fixed with 4% formaldehyde solution for 10 min at 6, 8, 10, 12, 18, 238 
and 24 h post infection (hpi), and permeabilized with 0.25% Triton X-100 for 10 min 239 
at ambient temperature. After blocking with PBS containing 3% bovine serum 240 
albumin (BSA), cells were incubated with mAb for 1 h at 37 °C. Unbound antibodies 241 
were removed with PBST three times and cells were incubated with anti-mouse IgG 242 
Alexa Fluor 488 (Zymed-Invitrogen, CA, USA) for 1 h. After staining with 4ʹ,6-243 
diamidino-2-phenylindole (DAPI) for 10 min, coverslips were examined using a Zeiss 244 
Laser confocal fluorescence microscope (Nikon, JPN). 245 
 246 
2.8. Plasmid construction for epitope mapping 247 
To map the epitopes of generated mAbs, a series of eukaryotic plasmids expressing 248 
truncated V proteins were constructed. Consecutive truncations were introduced to 249 
the V protein ORF of pFLAG-ZJ1-V by overlapping PCR using PfuUltra II Fusion HS 250 
DNA polymerase (Stratagene, Agilent, US). Primers and locations of truncated 251 
sequences are in Table 2, Table 3. PCR was 30 cycles of 98 °C 10 s, 58 °C 20 s and 252 
72 °C 8 min. After purification by PCR purification kits (Axygen), PCR products were 253 
digested with DpnI (Fermentas) at 1 U/μL at 37 °C for 1 h with inactivation at 80 °C 254 
for 10 min. Digested PCR products were directly transformed into E. coli DH5α. All 255 
plasmids were identified by sequencing (Sangon Biotechnology, Shanghai, China). 256 
 257 
2.9. Plasmid transfection 258 
HeLa cells at 70% confluence, seeded in 6-well plates, were transfected with 259 
pFLAG-ZJ1-V and derived recombinant plasmids using FuGENE HD transfection 260 
reagent (Promega, Madison, WI, USA) according to the manufacturer's instructions. 261 
Transfected cells were harvested at 48 h post transfection and subjected to FLAG-262 
tagged V protein detection by WB. 263 
 264 
2.10. Polypeptide design and detection 265 
To fine-map epitopes recognized by mAb 3D7, three polypeptides spanning amino 266 
acid (aa) 144–167 of V protein were synthesized by GL Biochem (Shanghai, China) 267 
were 144SPTSGPTTRGPAELWK159, 147SGPTTRGPAELWKQPGK163 and 268 
152RGPAELWKQPGKTAAS167. A panel of polypeptide mutants was synthesized 269 
based on 147SGPTTRGPAELWKQPGK163, in which certain aa residues were 270 
replaced by alanine (A) and named S147 A, G148 A, P149 A, T150 A, T151 A, 271 
R152 A, G153 A, P154 A, E156 A, L157 A, W158 A, K159 A and Q160 A. Purified 272 
His-VCD was the positive control and an irrelevant peptide (aa 40PQGKTKALSTA50 273 
from ZJ1 V protein) was the negative control. Reactivity of mAb 3D7 with each 274 
polypeptide was determined by ELISA and WB. 275 
 276 
2.11. Bioinformatics analysis 277 
Prediction of aa sequences, alignment of sequences and phylogenetic analysis used 278 
the MegAlign program in the Lasergene package (DNASTAR Inc., Madison, WI, 279 
USA). V protein sequences of 27 reference NDV strains of different genotypes were 280 
from EMBL/GenBank (Table 1). BepiPred-2.0 online software was used to predict 281 
sequential B-cell epitopes of NDV V protein 282 
(http://www.cbs.dtu.dk/services/BepiPred/). Amino acid sequences of NDV V 283 
proteins were sent to Swiss Model (http://swissmodel.expasy.org/) for modelling of a 284 
three-dimensional (3D) structure of NDV V protein, which was subjected to 285 
DiscoTope 2.0 Server for discontinuous B-cell epitope analysis (Kringelum et al., 286 
2012). 287 
 288 
3. Results 289 
3.1. Expression and purification of recombinant NDV ZJ1-VCD protein 290 
A His-tagged form of NDV V protein CTD polypeptide was highly expressed by pET-291 
28a-ZJ1/VCD in E. coli and had a molecular weight of 15 kDa as determined by 292 
SDS-PAGE, as predicted (Fig. 1A). Recombinant protein His-VCD was purified 293 
through Ni-chelating affinity chromatography under denaturing conditions and 294 
confirmed by WB with anti-His, in which a single band with the expected molecular 295 
weight of approximately 15 kDa was observed (Fig. 1B). The recombinant protein 296 




Fig. 1. SDS-PAGE and Western blot assays for the recombinant CTD polypeptide of 301 
NDV V protein expressed from pET-28a-ZJ1/VCD in E. coli BL21. (A) SDS-PAGE 302 
assay of His-tagged form of the ZJ1 V protein CTD region expressed in E. coli. (B) 303 
WB assay of the purified recombinant protein His-VCD using anti-His. M, PageRuler 304 
prestained protein ladder; 1 and 6, E. coli BL21 lysate (negative control); 2, total His-305 
VCD expressed from pET28a-VCD; 3, His-VCD expressed in the supernatant; 4 and 306 
7, His-VCD expressed in inclusion bodies; 5, His-VCD purified from inclusion bodies. 307 
 308 
3.2. Generation of the mAb 3D7 against NDV V protein 309 
Five hybridoma cell lines were acquired and only one stably produced antibodies 310 
that reacted strongly with His-VCD in indirect ELISA and IFA (data not shown). This 311 
mAb clone was designated as 3D7. Using a commercially available isotyping kit 312 
(Roche), the mAb 3D7 heavy chain was determined to be IgG1 and the light chain 313 
was к. The ascites fluid of mAb 3D7 was produced and purified to the final 314 
concentration of 1.5 mg/mL. 315 
 316 
3.3. Specificity of the mAb 3D7 for different NDV genotypes 317 
As shown in Fig. 2A, the mAb 3D7 reacted with the recombinant His-tagged V 318 
protein expressed by pFLAG-ZJ1-V in DF1 cells. A single band of about 35 kDa was 319 
observed, the same as the result with anti-His antibodies. Further, the purified ZJ-1 320 
(class II, genotype VII), JS10 (class I), La Sota/46 (class II, genotype II), Herts/33 321 
(class II, genotype IV) and ND167 (class II, genotype VI) viruses were detected in 322 
WB to determine the reactivity of mAb 3D7 with distinct NDV virions. Both P and V 323 
protein were detectible in all of the NDV virions using antiserum anti-PNT; however, 324 




Fig. 2. Reactivity and specificity assay of mAb clone 3D7 by Western blot. (A) WB 329 
assay of the His-tagged V proteins expressed by the recombinant plasmid pFLAG -330 
ZJ1-V in DF1 cells using anti-His or mAb 3D7 antibodies. (B) WB assay of V and P 331 
proteins contained in different NDV virions using the mAb 3D7 and antiserum anti-332 
PNT. (C) WB assays of the V and P protein expressed in NDV-infected DF1 cells. 333 
 334 
This result was confirmed in NDV-infected DF1 cells. Using mAb 3D7, V protein with 335 
a molecular weight of 35 kDa was detected only in ZJ1-infected DF1 cells (Fig. 2C), 336 
but not any other NDV-infected cells, involving JS10 (class I), V4 (class II, genotype 337 
I), La Sota/46 (class II, genotype II), Mukteswar, HM (class II, genotype III), Herts/33 338 
(class II, genotype IV), ND132, ND167 (class II, genotype VI) and F48E8 (class II, 339 
genotype IX). As a comparison, P protein were detected in those NDV strains-340 
infected cells, with varying molecular weights of around 55 kDa. This result was 341 
probably due to different phosphorylation levels of P protein in different strains (Qiu 342 
et al., 2016c). 343 
 344 
Indirect ELISA assay was performed and the titer of mAb 3D7 against purified His-345 
VCD protein was 1:3200. The mAb 3D7 never react with all the virus detected except 346 
for ZJ1. The titer was 1:800. 347 
 348 
3.4. Identification of B cell epitopes recognized by the mAb 3D7 349 
The epitopes recognized by mAb 3D7 was mapped in WBs with NDV V protein and 350 
its derived protein mutants. As shown in Fig. 3A, the mAb 3D7 did not react with V 351 
protein when aa 132-161 or 152-181 were truncated; by contrast, the truncation of 352 
172-201, 192-221, 212-231 from V protein never influenced the reactivity of 3D7. 353 
Subsequent experiments showed that truncated V protein mutants without peptides 354 
spanning aa 140-154, 141-155, 142-156, 143-157, 144-158, 145-159, 146-160, 147-355 
161, 148-162, 149-163, 150-164, 151-165, 152-166, 153-167, 154-168, 155-169, 356 
156-170 or 157-171 were not recognized by mAb 3D7 (Table 3 and Fig. 3B). These 357 
peptides contain 154PAEL157 as the common aa, suggesting that mAb 3D7 358 





Fig. 3. Mapping of the epitope recognized by mAb 3D7. (A) WB detection of a panel 364 
of recombinant V protein, in which 30 aa were consecutively truncated in the CTD 365 
region. All the V protein mutants and their deleted regions are listed in Table 2. (B) 366 
WB detection of a panel of recombinant V protein, in which 15 aa were consecutively 367 
truncated in the ORF spanning from aa 138 to 174. All the V protein mutants and 368 
their deleted regions are listed in Table 3. (C) Dot blots detection for the mAb 3D7 369 
using synthesized peptides. The labels 144-159, 147-163 and 152-167 indicate the 370 
peptides 144SPTSGPTTRGPAELWK159, 147SGPTTRGPAELWKQPGK163 and 371 
152RGPAELWKQPGKTAAS167, respectively. S147 A, G148 A, P149 A, T150 A, 372 
T151 A, R152 A, G153 A, P154 A, E156 A, L157 A, W158 A, K159 A and Q160 A 373 
indicate the polypeptide mutants based on 147SGPTTRGPAELWKQPGK163, in 374 
which certain aa was replaced by alanine. All the positive results are labeled with △ 375 
under the blot. (D) Dot ELISA detection for the mAb 3D7 using synthesized peptides. 376 
Error bars represent standard deviation. The OD450 value of synthesized peptides 377 
were compared with the positive control by using the Student’s t-test and the ELISA 378 
readings that were significantly different from the positive control are labelled * 379 
(P < 0.05). 380 
 381 
Fine mapping of the epitope was performed by dot blots and dot ELISAs using three 382 
synthesized peptides spanning aa 144-159, 147-163 and 152-167 of V protein. 383 
Reactivity of 3D7 with peptide 152-167 in dot blots was impaired compared to 384 
peptides 144-159 and 147-163 (Fig. 3C). In dot ELISAs, all three peptides were 385 
recognized by 3D7. The OD450 of peptide 152-167 was slightly lower than other 386 
peptides (Fig. 3D). This result suggested that aa region 147-159 was involved in 387 
formation of the epitope, but only the common aa sequence 152RGPAELWK159 of 388 
these peptides was essential. A panel of point mutations was introduced into the 389 
synthesized peptides. Removal of residues at R152, G153, E156, W158 and K159 390 
blocked recognition by 3D7 in dot blots; while the residue removal at S147, G148, 391 
P149, T150 and T151 did not influence the reactivity with 3D7. Besides, the mutation 392 
of P154 and L157 compromised mAb reactivity. Similar results were observed in dot 393 
ELISA results, the ELISA readings of 3D7 with the peptide mutant R152 A, G153 A, 394 
E156 A, W158 A and K159 A were significantly lower than the positive control. In 395 
addition, residue K159 was not recognized by the mAb in dot blot assays but was 396 
detectible in dot ELISA assays (Fig. 3C and D). 397 
 398 
3.5. Protein modelling and B-cell epitope analysis of NDV V protein 399 
The complete 3D structure of the NDV V protein was modelled according to the 400 
crystal structure of its counterpart of PIV5 (Fig. 4). The 3D7-recognized epitope was 401 
in the region spanning aa 140–171, all of which was exposed on the surface of V 402 
protein. The region 147-159, determined to be recognized by 3D7 were marked in 403 
the 3D structure of V protein. The V protein structure displayed that the crucial 404 
peptide 154PAEL157 of the 3D7 recognized epitope was not in a same plane with aa 405 
147-151, suggesting that aa 147-151 was not a crucial element for direct mAb 406 
binding. The linear B-cell epitopes of the NDV V protein was predicted from the 407 
primary protein sequences and the discontinuous B-cell epitopes was predicted 408 
based on the 3D structure, all of which covered the identified 3D7-recognized 409 




Fig. 4. Relative localization of the identified epitopes in the predicted 3D structure of 414 
the NDV V protein. The three-dimensional structure of the NDV V protein was 415 
modelled by the online services Swiss Model. The identified mAb 3D7-recognized 416 
peptide 152RGPAELWK159 and its structurally supporting part is labeled blue and red 417 
in the figure. The red areas represent oxygen and the blue areas indicate nitrogen. 418 
The model on the left is the predicted V protein structure with the calculated surface 419 
structure; while the model on the right displays the atoms of the mAb 3D7-420 
recognized peptide in a NDV V protein backbone without showing the surface 421 
structure. (For interpretation of the references to colour in this figure legend, the 422 
reader is referred to the web version of this article.) 423 
 424 
3.6. Specificity and conservation of the epitope among NDV strains 425 
V proteins from distinct NDV genotypes (Table1) were aligned for analysis. The mAb 426 
clone 3D7-recognized epitope 147SGPTTRGPAELWK159 and its surrounding 427 
region aa 140–146 and 160–171 were conserved among genotype VII NDV strains; 428 
however, the epitope shared low identity among other genotypes (Fig. 5), indicating 429 
that these sequences were only conserved in specific genotypes. The epitope 430 
recognized by mAb clone 3D7 was not in the zinc finger structure of V protein and 431 
was likely not a crucial element for NDV V protein, suggesting it as a potential target 432 




Fig. 5. Alignment of the identified epitope in the V proteins of NDV strains from 437 
diverse genotypes. V protein sequences from the 27 reference NDV strains of 438 
different genotypes were from the EMBL/GenBank (Table 1). Prediction of amino 439 
acid (aa) sequences, alignment of sequences and phylogenetic analysis were 440 
performed using the MegAlign program in the Lasergene package (DNASTAR Inc. 441 
Madison, WI, USA). The aa sequence that resembled the consensus sequence is 442 
indicated by a “.”. The region of the mAb 3D7-recognized peptide 443 
152RGPAELWK159 identified in the different NDV strains is boxed in the figure. 444 
 445 
3.7. Expression of V protein during genotype VII NDV infection 446 
To determine if mAb clone 3D7 could be used as a tool for immune-detection, 447 
dynamic expression of the V protein in NDV-infected cells was surveyed by IFAs and 448 
WBs. Firstly, the WB assay of NP protein showed that NDV was propagated in the 449 
infected cells. The mAb clone 3D7 reacted with V protein in ZJ-1-infected cells (Fig. 450 
6). V protein was detectable at 6 hpi as early as NP of NDV, suggesting it was likely 451 
expressed early during the virus’s replicative cycle. Similar results were observed by 452 
IFAs (Fig. 7). V protein was initially detected at 6 hpi, scattered in the cytoplasm with 453 
dotted distribution. From 8 hpi to 12 hpi, V protein accumulated in the cytoplasm and 454 
moved towards the periphery of the host cell nucleus. At 18 hpi, some nuclei of 455 
infected cells were surrounded by V protein. A large area of syncytia was observed 456 
at 24 hpi, and V protein was observed in the middle of the syncytia surrounded by 457 




Fig. 6. Dynamic expression of V protein in DF-1 cells infected with the NDV strain 462 
ZJ1 by WB. DF-1 cells were infected with NDV ZJ1 at MOI 5 and collected at 6, 12, 463 
18, 24 hpi. Lysates from cells were immunoblotted with the indicated 3D7, anti-NP 464 




Fig. 7. Dynamic expression of V protein in DF-1 cells infected with the NDV strain 469 
ZJ1 by IFA. DF-1 cells were infected with NDV ZJ1 at a MOI of 5 and harvested at 6, 470 
8, 10, 12, 18, 24 hpi. Cells were double stained with the mAb3D7 for V protein 471 
and 4′,6′-diamidino- 2-phenylindole (DAPI) for nuclei. The upper panel of figures 472 
show the V protein (green), while the lower figures show overlapping of V protein 473 
(green) and DAPI (blue). (For interpretation of the references to colour in this figure 474 
legend, the reader is referred to the web version of this article.) 475 
 476 
4. Discussion 477 
It has been reported that NDV V protein plays an important role in facilitating virus 478 
replication in infected cells via antagonizing cellular IFN signaling (Huang et al., 479 
2003; Park et al., 2003b; Qiu et al., 2016b). The V proteins from distinct NDV strains 480 
showed different interferon antagonistic activities (Alamares et al., 2010), albeit the 481 
molecular mechanism is unclear since there is little information about the structure 482 
and functional domains of NDV V protein. Mapping mAbs binding peptides may shed 483 
light on the V protein structure analysis. In this study, a NDV V protein-reactive Mab 484 
3D7 was generated. The reactivity of this mAb was limited to genotype VII strain and 485 
could be genotype specific (Fig. 2). To analyze the specificity of mAb 3D7, epitope 486 
mapping was performed based on detection of consecutive truncated His-tagged V 487 
proteins and synthesized peptides. The results showed that the epitope recognized 488 
by mAb 3D7 was located in aa 147–159, and in which peptide 152RGPAELWK159 489 
was essential (Fig. 3). 490 
 491 
The epitope (152RGPAELWK159) that we identified in NDV V protein was located at 492 
a region after the RNA editing site, which was flanked by two important functional 493 
regions, including N-terminal domain of P protein (Karlin et al., 2003; Qiu et al., 494 
2016c) and CTD (Horvath, 2004b); nevertheless, there is rare information regarding 495 
this region of NDV V protein at present. Based on the crystal structure of SV5 V 496 
protein (Li et al., 2006), the 3D structure of NDV V protein was established using the 497 
primary sequence. The predicted 3D structure provides potential useful structural 498 
information about the function and antigenic characteristics of the V protein. The 499 
predicted V protein structure displayed that the aa 147-159 of V protein was exposed 500 
on the protein surface and the core part peptide 152RGPAELWK159 formed a 501 
pocket, which would be recognized by the mAb. Furthermore, the reactivity of 502 
peptide 152-167 with 3D7 was weaker than peptide 144-159 and 148-163, 503 
suggesting that the region of aa 147-151 structurally contributed to epitope 504 
presentation on the V protein surface although it was not indispensable for mAb-505 
epitope interaction, which was supported by the 3D structure of V protein. 506 
 507 
One purpose of our study was to determine if V protein could be used as a tool for 508 
quick differentiation of genotypes and subgenotypes. Different from their 509 
counterparts in other paramyxoviruses, V protein NDVs are reported to be a 510 
structural component of virions (Lamb and Kolakofsky, 2002; Steward et al., 1995), 511 
which is confirmed by our results (Fig. 2). It suggested that V protein can be used as 512 
a detection target for NDV virion. Bioinformatics analysis of the NDV V protein 513 
revealed that aa 147-159 of V protein, especially the core peptide 514 
152RGPAELWK159 was exposed on the protein surface and displayed strong 515 
antigenicity for B-cell recognition based on the online analysis (Table 4), making it a 516 
good target epitope for detection. 517 
 518 
The identified and predicted B-cell epitopes were compared (Fig. 5). The identified 519 
epitope region aa 147–159 overlapped with predicted epitopes aa 141-148 and aa 520 
150-173. Furthermore, the core peptide 152RGPAELWK159 was totally included in 521 
the predicted epitopes aa 150-173. Not only linear epitope but the predicted 522 
discontinuous epitope aa 141–163 contained all the region recognized by mAb 3D7, 523 
suggesting the peptide would contribute to the formation of conformational epitopes. 524 
All the above results indicated that the region of NDV V protein recognized by mAb 525 
3D7 was highly immunogenic. 526 
 527 
The mAb only react with genotype VII strain and the sequence alignment indicated 528 
that the sequence of aa 140-171 of NDV V protein varied among genotypes but was 529 
conserved among NDV strains belonging to the same genotype. Importantly, the 530 
152RGPAELWK159 was conserved in genotype VII NDV strains, suggesting that the 531 
mAb clone 3D7 recognized an epitope specific for genotype VII or VIId. Defining 532 
conserved epitopes can contribute to the development of epitope-based diagnosis 533 
methods. It is widely known that most of the prevalent virulent NDV isolates belong 534 
to class II, genotype VII; meanwhile, the class I and class II non-virulent strains are 535 
spread worldwide due to live vaccine administration and natural infection (Kim et al., 536 
2007; Ramey et al., 2013). The limited genetic and antigenic diversity of NDV 537 
genotypes makes quick diagnosis complicated and difficult (Miller et al., 2010). Since 538 
the epitope recognized by mAb clone 3D7 was conserved in the genotype VII NDV 539 
strains, it could be a potential targeting site for NDV genotype and subgenotype 540 
differentiation. However, the NDV isolates used for detection in this study is limited, 541 
one cannot rule out the possibility that there would be some NDV variants with 542 
different reactivity with 3D7. More detection is required before it can be used for 543 
clinical applications. Since the 3D7-recognized region displayed genotype-specific 544 
conservation, it can be used as an immunogen to establish more genotype-specific 545 
mAbs, or directly used for epitope-based genotype differentiation. 546 
 547 
It is found in this study that the V protein-specific mAb clone 3D7 could be applied to 548 
various assays. The expression levels and cellular movement of V protein during 549 
viral replication were determined, since the subcellular localization of V protein 550 
during NDV replication has not been previously reported. Dynamic expression of V 551 
protein in NDV-infected cells was seen in IFAs and WBs (Fig. 6, Fig. 7). Scattering of 552 
V protein in the cytoplasm was initially detectible at 6 hpi, and the protein moved to 553 
the periphery of the host cell nucleus in the process of infection. At late stage of 554 
infection, a mass of V protein was observed around the nuclei of infected cells. This 555 
result showed the subcellular movement of NDV V protein in the process of IFN 556 
antagonism. In response to NDV infection, latent cytoplasmic STAT proteins are 557 
phosphorylated on tyrosine by the Janus family of tyrosine kinase (JAK) enzymes 558 
and form a heterotrimer of phosphorylated STAT-1, STAT-2 and IRF-9. 559 
Subsequently, this heterotrimer translocates to the nucleus and binds to cis-acting 560 
DNA elements to activate the IFN-I-stimulated antiviral genes (Horvath, 2004a, b; 561 
Samuel, 2001). V protein has IFN-antagonist activity in the CTD, which promotes 562 
degradation of STAT1 and blocks IFN signaling (Alamares et al., 2010; Park et al., 563 
2003b). Our results showed that V protein tend to accumulate around the nuclei of 564 
infected cells, suggesting it might act on STAT-1 protein in the course of nuclear 565 
import of phosphorylated STAT-1. 566 
 567 
5. Conclusion 568 
The mAb clone 3D7 against NDV V protein was isolated and the mAb recognized 569 
epitope was identified to be 152RGPAELWK159. This peptide was located in a 570 
region which was varied in sequence among genotypes but conserved in sequence 571 
and structure among NDV strains in the same genotype. The generated V protein-572 
specific mAb clone 3D7 could be applied to various assays and helped us to 573 
determine the location of V protein during NDV replication in infected cells. These 574 
results extend our understanding of the antigenic structure of V protein and the 575 
function of V protein during NDV infection. They also provide a foundation for 576 
development of novel, epitope-based genotype differentiation of NDV genotypes. 577 
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